Despite the clonal origin of most tumors, their tremendous heterogeneity suggests that cancer progression springs from the combined forces of both genetic and epigenetic events, which produce variant clonal populations, together with the selective pressures of the microenvironment, which promote growth and, perhaps, dissemination of variants with a specific set of characteristics. Although the importance of genetic mutations in cancer has long been recognized, the role of epigenetic events has been suggested more recently. This review focuses on the genetic and epigenetic molecular mechanisms involved in cancer onset and progression, and discusses the possibility of new strategies in the development of anticancer treatments.
Introduction
Human cancer is widely recognized as an intricate multistep process that involves malfunction in protooncogenes, tumor suppressor genes, and other key cellular genes implicated in cell proliferation, differentiation, survival, and genome integrity (Hahn et al., 1999; Hahn and Weinberg, 2002) . Perhaps surprisingly, the whole process of cell transformation has been shown to be not so easy to achieve, due to the intrinsic resistance to transformation at both cellular and organismic levels; in fact, it may take decades to be accomplished through subsequent rounds of clonal selection. Owing to this peculiar mechanism, several different combinations of gene inactivations can be found in the genome of morphologically similar human cancers, and this phenomenon is possibly responsible for the enormous heterogeneity in outcomes of patients with the same clinical diagnosis.
Basically, two major classes of mutations can be considered: (a) 'gatekeeper' mutations, which compromise the control of cell proliferation, and (b) 'caretaker' mutations, responsible for genetic instability (Cairns, 1975; Kinzler and Vogelstein, 1997; Frank, 2003; Russo et al., 2003) . Alterations in these cancer susceptibility genes may result through either genetic or epigenetic mechanisms; while the genetic abnormalities are associated with changes in DNA sequence, the epigenetic events may lead to changes in gene expression without changes in DNA sequence through different mechanisms. Methylation of DNA and remodeling of chromatin via histone proteins, are believed to be the most important epigenetic changes, whose role in cancer has been recently underscored.
This review focuses on the genetic and epigenetic molecular mechanisms involved in cancer formation and progression; moreover, the possibility of new strategies in the development of anticancer treatments is discussed.
From the normal control of the cell cycle to tumorigenesis
Cancer is intimately related to the process of development and growth. Every gene implicated in the progression to a cancerous phenotype plays a fundamental role, during embryo growth and development. Genes that regulate these processes are thus important targets of research to understand differences in the control of gene expression between normal and cancer cells and to identify new candidates for anticancer drug development.
The cell cycle is a very finely tuned process and responds to the specific needs of any specific tissue or cell (Hartwell and Kastan, 1994) . Normally, in an adult tissue, we observe a delicate balance between programmed cell death (apoptosis) and proliferation (cell division) which is responsible for the dynamic steady state. Disruption of this equilibrium by loss of cell cycle control may lead to hyperplasia and eventually to tumor development (Hanahan and Weinberg, 2000) .
Mutations in oncogenes and tumor suppressor genes and alterations in their signaling pathways have been identified to be involved in the uncoupling of the cell cycle from its normal regulatory parameters (Gan et al., 2003) . Gatekeeper genes function by directly controlling cell growth, thus inhibiting proliferation, leading to apoptosis and/or promoting terminal differentiation . These genes are frequently mutated in both sporadic and hereditary tumors, and their functional loss is rate limiting for tumor growth of a specific tissue type. Alteration of a particular gatekeeper gene can lead to the development of a particular form of predisposition to cancer (Kinzler and Vogelstein, 1997) . Caretaker genes are involved in the maintenance of genomic stability by reducing the mutation rates in gatekeepers and oncogenes. Mutations in these genes are frequently found in hereditary tumors (Kinzler and Vogelstein, 1997) . Consequently, an altered gatekeeper gene could affect mainly tumor initiation, while a caretaker gene could accelerate the tumor progression, even if in certain cases their functions may partly overlap; as such the same gene may act either as a gatekeeper or as a caretaker (Frank, 2003) .
Alteration of cell cycle checkpoints
The genetic evolution of normal cells into cancer cells is largely determined by the fidelity of DNA replication, repair, and division. The switch between phases is a hallmark of the cell cycle, and the control mechanisms that restrain cell cycle transition or induce apoptotic signaling pathways after cell stress are known as cell cycle checkpoints (Sherr, 2000) . Intrinsic and extrinsic mechanisms act to control and regulate the cell cycle. The intrinsic mechanisms appear at every cycle and the extrinsic mechanisms only act when defects are detected (Sandal, 2002) . Loss of these control mechanisms by genetic and epigenetic events results in genomic instability, accumulation of DNA damage, uncontrolled cell proliferation, and eventually tumor development. Cyclin-dependent kinases (Cdks), cyclins, Cdk inhibitors (CKIs), Cdk activator kinases (CAKs), tumor suppressor genes (gatekeepers, caretakers, and landscapers), and oncogenes are the main players in the mammalian cell cycle.
Cells escape growth control and evade cell death by targeting key oncogenes and tumor suppressor genes in molecular pathways. The pRb (pRb/p16 INK4a /cyclin D1) and p53 (p14 ARF /mdm2/p53) pathways are the two main cell cycle control pathways frequently targeted in tumorigenesis, and the alterations occurring in each pathway depend on the tumor type (Giaccia and Kastan, 1998; Dyson, 1998; Macaluso et al., 2002; Sherr and McCormick, 2002) . The importance of these pathways in cellular growth control is underscored by the observation that members of these pathways are found mutated in all human cancers. Recently, it has been reported that among the cell cycle proteins, the p16 INK4a / pRb and ARF/mdm2/p53 cell cycle arrest pathways play a prominent role in glial transformation (Konopka and Bonni, 2003) . Furthermore, many other studies have revealed the molecular and genetic interaction between the pRb and p53 pathways (Stewart et al., 2001; Yamasaki, 2003 (Bartkova et al., 1996; Maelandsmo et al., 1996) .
Many of the antiproliferative signals that regulate the cell cycle clock are funneled through the retinoblastoma protein (pRb) and its related proteins, p107 and pRb2/ p130 (Cinti and Giordano, 2000) . At least two opposing enzymatic reactions control the activity of pRb family members: phosphorylation and dephosphorylation (Cinti and Giordano, 2000) . The overall mechanism of tumor formation seems to consist of inhibitory effects on the pRb pathway controlling the G1-S transition and it is also accomplished by alterations in other regulatory components of this pathway resulting in decreased tumor suppression. Mutations and deletions of the Rb gene have been reported in several human tumors, and inherited allelic loss of Rb confers increased susceptibility to cancer formation (Yamasaki, 2003) . Nevertheless, the Rb-related Rb2/p130 gene plays a pivotal role in the negative control of the cell cycle and in tumor progression as well (Paggi and Giordano, 2001) .
Loss-of-function mutations in p16
INK4a
, a cell cycle regulatory protein involved in tumor suppression in the pRb pathway, occur frequently in human cancers (Ruas and Peters, 1998; Sherr, 2000) . p16
INK4a blocks cell cycle progression by binding Cdk4-6 and inhibiting the action of D-type cyclins. Moreover, by inhibiting pRb phosphorylation, p16
INK4a can promote the formation of a pRb/E2F-repressive complex that blocks the G1-S progression of the cell cycle (Zhang et al., 1999) . In fact, it has been reported that both cyclin D1 overexpression and p16
INK4a protein alteration produce persistent hyperphorylation of pRb, resulting in evasion of cell cycle arrest (Beasley et al., 2003) .
Small homozygous deletions are the major mechanism of p16
INK4a inactivation in various primary tumors such as glial tumors and mesotheliomas, while mutations are not commonly reported (Jen et al., 1994; Ohta et al., 1994; Cairns et al., 1995; Zhang et al., 1998) . Moreover, aberrant methylation of p16
INK4a has been shown in cancer of the lung, breast, bladder, head and neck, colon, and esophagus (Gonzales-Zulueta et al., 1995; Woodwock et al., 1999; Esteller et al., 2001) .
Increasing evidence indicates that perturbation of cyclins is one of the major factors leading to cancer initiation and progression. Convincing results indicate that a combination of cyclin/Cdks, and not a single kinase, executes pRb phosphorylation and that each one of these complexes phosphorylates specific pRb-phosphorylation sites (Mittnacht, 1998) . Interestingly, the different kinases appear to be activated by distinct signal transduction pathways and in this context pRb phosphorylation may constitute a point of integration for these signals leading to cell cycle progression (Mittnacht, 1998) .
Recently, it has been reported that the activation of the MAPK kinase leads to pRb inactivation by sustaining cyclin levels and consequently activating Cdks (Kaelin, 1999; Zheng and Lee, 2000; Adams, 2001) . However, the signals linking receptor kinase activity to neutralization of pRb family members have not yet been fully elucidated. Constitutive cell surface kinase receptors and persistent phosphorylation/inactivation of the pRb family proteins (pRb, p107, and pRb2/p130) have been implicated in conferring uncontrolled growth to melanoma cells (von Willebrand et al., 2003) . Moreover, overexpression of cyclin D1 has been found in most human colon and breast cancers (Steeg and Zhou, 1998; Tetsu and McCormick, 1999) . In addition, it has been shown that there is an absolute requirement for the cyclin D1 overexpression in breast malignancy trasformation that cannot be complemented by the other related cyclins D2 and D3, suggesting a putative anti-cyclin D1 therapy highly specific for breast cancer (Yu et al., 2001) .
Taken together, the cell cycle regulatory genes most often altered in cancer are those involved in controlling the transition of cells from G1 into S phase by regulation of the pRb pathway. Moreover, the mechanisms disturbing the pRb pathway converge to a common goal: the release of E2F transcription factors from control of pRb family members and the uncontrolled expression of regulators that trigger an irreversible transition into the S phase and cell cycle progression, even in the absence of growth signals.
P14
ARF /mdm2/p53 pathway The p53 gene lies at the crossroads of multiple pathways controlling the cell fate in response to endogenous or exogenous insults and can be defined as either a gatekeeper or caretaker tumor suppressor. In fact, as an inducer of cell cycle arrest and apoptosis it may be considered as a gatekeeper, and as a 'guardian of the genome' that preserves genomic integrity, it appears to act as a caretaker (Giaccia and Kastan, 1998; Russo et al., 2003) . The suppression of apoptosis by inactivation of the p14 ARF /mdm2/p53 pathway appears to play an important role in tumor development. Moreover, due to the fact that p53 is the most frequently mutated gene in human cancer, it appears to be a crucial target for therapy with respect to tumor formation and elimination of the tumor cells (Ding and Fisher, 2002) . The check and balance that exists between pRb and p53 pathways involves the regulation of the G1-S transition and its checkpoints. Part of this network consists of an array of autoregulatory feedback loops where pRb and p53 signals exhibit very intricate interactions with other proteins known to play important roles in the determination of cell fate.
p53 is activated in response to UV irradiation, DNA damage, cellular stress, and the turnover of this shortlived protein is regulated by ubiquitination through mdm2 binding, leading to degradation by proteosomes and thereby limiting p53 accumulation (Haupt et al., 1997) . Moreover, p53 activates mdm2 transcription, ensuring a negative feedback regulation (Sherr, 2000) . The human p14 ARF protein is known to arrest the cell cycle in G1 and G2 phases and acts in the same p53 pathway. p14 ARF interferes with all the known functions of mdm2 and it has been shown that p14ARF binds the mdm2-p53 complex, resulting in a stabilization of both proteins (Sherr, 2000) . Significantly, p14ARF expression is positively regulated by members of the E2F family of transcription factors. This provides a link between the pRb family members and p53 pathways, suggesting a mechanism whereby the inactivation of pRb proteins leads to E2F release, p53 stabilization and functional activation. Furthermore, p53 activates the transcription of p21Cip/Kip, which is largely responsible for the p53-dependent G1 arrest in response to cellular stress and DNA damage. p21Cip/Kip regulates cyclin E/Cdk2 and cyclin A/Cdk2 complexes, both of which phosphorylate pRb, thus contributing to an irreversible transition into the S phase and cell cycle progression, even in the absence of growth signals. The accumulation of p21Cip/ Kip followed by inhibition of cyclin E/Cdk2 and cyclin A/Cdk2 complexes blocks the progression from G1 into S phase (Yamasaki, 2003) .
Deletion inactivation of p14 ARF has been reported in human cancers, but in those studies p16
INK4a was always codeleted (p14 ARF and p16 INK4a genes are both encoded by the INK4a/ARF locus at chromosomal region 9p21) (Fulci et al., 2000; Newcomb et al., 2000; Sarkar et al., 2000) . Moreover, recent studies have reported that epigenetic alterations such as CpG hypermethylation may be the first cause of the genetic silencing of p14 ARF , followed by p14 ARF loss of heterozygosity (LOH) and homozygous deletions. Hypermethylation of p14 ARF has been detected in primary colorectal, gastric, breast, and lung cancers (Iida et al., 2000; Zochbauer-Muller et al., 2001; Silva et al., 2003) .
Virtually, all human tumors deregulate either pRb or p53 pathways, and often both pathways simultaneously. In addition, the importance of pRb and p53 in preventing tumor formation was confirmed by mouse knockout studies, which showed that mouse embryo fibroblasts derived from p53À/À, p19À/À or pRb/p107/ p130À/À animal could be transformed by the activated Ras oncogene alone (Wei et al., 2003) .
Taken together, the disruption of the pRb/p16INK4/ cyclin D1 and p14ARF/mdm2/p53 pathways appear to be a common part of the life history of human cancers, independent of age or tumor type.
Molecular mechanisms of tumor progression and metastasis
Although the vast majority of tumors are clonal, there is tremendous heterogeneity in the tumor cell population. This suggests that tumor progression springs from the combined forces of genetic and epigenetic events, which produce variant clonal populations, together with the selective pressures of the microenvironment, which promote growth and, perhaps, dissemination of variants with a specific set of characteristics.
The genetic variability of tumor cells leads to the attainment of six functional capabilities that collectively dictate malignant growth: (1) self-sufficiency in growth signals; (2) insensitivity to growth-inhibitory (antigrowth) signals; (3) evasion of programmed cell death (apoptosis); (4) limitless replicative potential; (5) sustained angiogenesis; and (6) tissue invasion and metastasis (Hanahan and Weinberg, 2000) . While the genetic changes may occur in varying order, there is a consistency with the progression of changes that can be described, for each kind of cancer, by a set of staging criteria. Generally, tumors that result in metastases are stochastically considered to go through the following transitions: detachment from the primary tumor, invasion through a basement membrane and/or into surrounding tissue, intravasation, entering blood or lymphatic vessels, formation of tumor cell clusters, mechanical arrest or adhesion to the vessel wall in a distant organ, extravasation (exit from the vessel) and infiltration of the organ parenchyma, angiogenesis, and growth into a secondary tumor (Tonini et al., 2003) . It is possible, anyway, that each single human tumor can display in its evolution not only its own sequence of events, but also its specific or unique spectrum of genetic changes (Hanahan and Weinberg, 2000) .
Interestingly enough, more recent views underline the possibility that mutations conferring the metastatic capability can be acquired relatively early during the multistep road to cancer progression. This concept springs from the evidence that genes involved in metastasis formation do not seem to confer increased proliferative benefits. This vision implies that: (1) the metastatic potential of a cell clone can be present very early before the appearance of a metastasis; (2) genes or genetic changes uniquely connected to the metastatic phenotype do not exist; and (3) even small primary tumors-at relatively early stages in tumorigenesismay show the ability to metastasize (Bernards and Weinberg, 2002) . Unfortunately, numerous clinical data validate this last implication. In addition, these schematic frameworks, in order to reach a better completion, should be integrated with some realistic properties of the biological systems, such as stochasticity and nonlinearity (Gatenby and Maini, 2003) .
Still we cannot explain how this required set of mutations, able to force a normal cell to become a highly malignant cancer cell, could take place over the course of the patient's lifetime. In fact, the statistical rate of mutation in normal cells is too low to justify the whole range of mutational events described above. In effect, this can be explained only with the additional characteristic of 'genetic instability', a phenomenon that implies that the genome of a mutated (preneoplastic) cell becomes per se unstable, thus increasing the chance of further mutational events and shortening the predicted time to obtain the full range of mutations (Hahn and Weinberg, 2002) . Indeed, cancer cells display almost constantly instability either in DNA sequence or in karyotype (Lengauer et al., 1998) . This is essentially correlated with 'caretaker' mutations and with the consequent unsuccessful elimination of damaged cells. New implications in this phenomenon appear from the effects of the human papillomavirus E7 (Duensing et al., 2001) and of the adenovirus E1A (De Luca et al., 2003) oncoproteins, whose expression is able to induce supernumerary centrosomes, driving to chromosome missegregation and to the generation of aneuploid cells (Lavia et al., 2003, this issue) .
Clinical implications
Invasion and metastasis are complex processes, and their genetic, epigenetic and biochemical causes are still largely unknown (Kim et al., 1998) . Molecular analysis of cancer cells in early and late stages of tumors has strongly indicated that alterations in tumor suppressor genes and oncogenes accumulate during tumor progression, and have led to the hypothesis of a multistage carcinogenesis in colorectal cancer progression, which now is widely accepted as a genetic model of tumor progression (Kinzler and Vogelstein, 1996) . No other scheme of epithelial cancer progression has been described in such detail, with the exception of a model postulated for pancreatic cancer, where an adenomacarcinoma sequence is proposed (Brat et al., 1998) .
An important goal of clinical oncology is to identify the molecular markers to use in evaluating the prognosis in cancer patients. Thus, more studies have investigated the association between oncogene alterations in tumor cells and prognosis of the patients with various tumor types. In general, amplification of oncogenes occurs late during tumor progression and correlates well with the clinical aggressiveness of the tumors, while the prognostic significance of tumor suppressor gene inactivation still remains unclear or controversial in several tumor types.
For instance, amplification of the N-Myc oncogene is a valuable prognostic marker for patients with neuroblastoma (Brodeur et al., 1984) ; amplification and overexpression of the c-erbB-2 oncogene are considered markers of aggressiveness in ovarian and breast cancer (Slamon et al., 1989) . Moreover, numerous studies on the hematological malignancies, pancreatic, colorectal, and non-small cell lung cancers have evaluated the potential role of Ras mutations as a negative prognostic factor but these results are conflicting Macaluso et al., 2002) . In addition, clinically, mutations of ras occur in the early stage of tumor progression in several types of cancer, in particular in colorectal cancer; thus, it is still questionable whether mutations of ras have a function of enhancing the metastatic potential of tumor cells.
During the last two decades, several studies have indicated that various genes inducing or suppressing metastasis are differentially expressed between metastatic and nonmetastatic cells. For instance, the forced expression of the nm23 and Elm 1 genes has been shown to suppress the metastatic activity of tumor cells, while the p9Ka/mta 1 gene induced metastasis (Leone et al., 1991; Toh et al., 1994; Hashimoto et al., 1998) . Other genes such as KAI1, KiSS-1 and Tiam-1 have also shown to have functions in suppressing or inducing metastasis (Habets et al., 1994; Dong et al., 1995; Lee and Welch, 1997) .
However, the expression profiles of these genes in human cancer do not always correlate with the metastatic potential of the cells, and it still remains unclear whether they are clinically valuable for the prediction of metastatic potential in cancer patients.
Loss of junctional contact between adjacent epithelial cells and cell-extracellular matrix association are essential prerequisites for tumor cell detachment from the primary tumor site (Aplin et al., 1998) . Several classes of protein are participating when tumor cells exhibit an invasive or metastatic phenotype and adhesion molecules on the cell surface play an important role in regulating cell migration and the potential of cells to metastasize (Skubitz, 2002) . Important changes occur in genes that regulate extracellular matrix homeostasis such as matrix metalloproteases (MMPs) and their tissue inhibitors (TIMPS), plasminogen activator/ plasmin system, angiogenesis, and lymphangiogenesis (Cornelius et al., 1998; Tempia-Caliera et al., 2002) .
Epigenetic alterations in cancer
Epigenetic changes alter the heritable state of gene expression and chromatin organization without change in DNA sequence. In this context, it is worth underscoring that extensive studies on expression profiling and functional genomic can possibly fail in detecting a number of aberrant epigenetic modifications in malignant phenotypes, due to the intricate cascade of events comprised between these regulatory events and the multitude of gene expression modifications under their direct or indirect control. For instance, epigenetic mechanisms such as DNA methylation and histone methylation and deacetylation have been shown to affect the transcription of key genes involved in the regulation of cellular growth, differentiation, apoptosis, transformation, and tumor progression (Laird and Jaenisch, 1996; Muegge et al., 2003; Sutherland and Costa, 2003; Yasui et al., 2003) .
These events are mediated by the formation of transcriptionally repressive chromatin states resulting in gene silencing (Hajes and Hansen, 2001) . It has been proposed that DNA methylation, histone deacetylation, and histone methylation may work together to establish a repressive chromatin environment and silence gene expression (Bird and Wolffe, 1999; Cameron et al., 1999) . In addition, the formation of transcriptional repression complexes, such as DNA methyltransferase (DNMT) 1/histone deacetylase (HDAC) or methyl-CpG binding proteins/HDAC, is emerging as an important mechanism in gene expression regulation (Nan et al., 1998; Strahl and Allis, 2000) . Aberrant recruitment of HDAC activity has been associated with the development of certain human cancers (Nan et al., 1998) , and changes in the pattern of CpG-methylation appear to be an intrinsic feature of human malignancy (Jones et al., 1998) . There are different types of protein complexes capable of altering chromatin, and these may act in a physiological context to modulate DNA accessibility to the transcriptional machinery (Zini et al., 2001; Vignali et al., 2000) . Recently, our studies have shown that pRb2/p130 can regulate the transcription of ER-a and p73 genes by recruiting specific chromatin-modifying enzymes in multimolecular complexes on the ER-a and p73 promoters (La Sala et al., 2003; Macaluso et al., 2003) (Figure 1) . Moreover, it has been suggested that chromatin remodeling, as a result of histone deacetylation and methylation, is the primary event in abrogating transcriptional initiation and that CpG island hypermethylation establishes a permanent state of gene silencing (Nephew and Huang, 2003) . Accumulating evidence indicates that CpG island hypermethylation is an early event in cancer development and may precede the neoplastic process (Nephew and Huang, 2003) . Methylation-associated silencing has been demonstrated in various genes, including tumor suppressor genes such as p15, p16, p73, VHL, pRb, and MLH1 (Jones and Baylin, 2002; Nephew and Huang, 2003) . For instance, it has been shown that colorectal adenomas have a relatively high frequency of methylation in multiple tumor suppressor genes and DNA repair genes such as hMLH1, and aberrant methylation is an early event during tumorigenesis (Toyota et al., 2002) . Moreover, recent studies have suggested that aberrant methylation may be an early event inactivating cancer-related genes in lung cancer (Zochbauer-Muller et al., 2002) .
Although the importance of genetic alterations in cancer has been long recognized, the appreciation of epigenetic changes is more recent. However, an increased body of research provides evidence that aberrant epigenetic mechanisms affect the transcription of key genes involved cell proliferation, differentiation, survival, and genome integrity and play an important role in cancer formation and progression. Therefore, the re-expression of epigenetically silenced genes could provide a means to suppress tumor growth and to increase sensitivity to anticancer drugs.
Therapeutic strategy and cancer
Increased knowledge of the molecular mechanisms regulating cell cycle progression and involved in tumor formation suggests that modulators of Cdks (Flavopiridol, UCN-10, paullones, and durubines) and cyclins could be potent therapeutic agents in cancer therapy (Senderowicz, 2000; Owa et al., 2001) . Moreover, several anticancer agents targeting Cdks are currently tested in clinical trials and other studies have shown promising results regarding potential anticancer agents in vitro (Meijer, 1995; Schultz et al., 1999; Senderowicz, 2003) .
Furthermore, other approaches have been used to explore the effectiveness of therapeutic agents, such as adenovirus-associated viruses which selectively infect and kill cells that lack p53 (Raj et al., 2001) ; antisense oligonucleotides that target cell cycle regulators such as cyclin D1 (Saikawa et al., 2001) , or that modulate DNA methylation, such as DNMT1. Ongoing clinical trials are evaluating the safety and efficacy of agents affecting epigenetic changes in cancer patients (Kalebic, 2003) . Although several anticancer agents have been developed, the disease remains difficult to cure. However, the understanding of complex molecular signaling pathways involved in cancer formation and progression still remains the most important goal in cancer research.
